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Abstract: Herpes simplex virus (HSV) infection is a highly prevalent condition responsible 
for signiﬁ  cant morbidity and occasional mortality each year. Approximately half of all patients 
infected by HSV will experience at least one recurrence in their lifetime. For these recurrences, 
traditional therapy has included both suppressive and episodic treatment with nucleoside analogs. 
In regards to episodic treatment, 2- to 5-day oral regimens are best studied and most commonly 
reported. As with any medical condition having a well-understood mechanism of action and 
targeted treatment, therapeutic intervention is only as effective as allowed by patient compliance. 
Based on these concerns, recent studies have focused on shorter, less complicated, and more 
affordable options. This review delineates the evidence for single-day treatments of orolabial 
and genital herpes. Randomized, double-blind studies of both valacyclovir and famciclovir as 
single-day episodic therapy for HSV have been reported in the literature. Although no head-
to-head studies between the drugs have been performed, both regimens produced signiﬁ  cant 
improvement in healing time and symptom resolution over placebo. Single-day therapy for HSV 
infection is appealing for multiple reasons. First, it simpliﬁ  es the regimen, increasing likelihood 
of patient compliance. Additionally, it allows complete delivery of the medication at the onset 
of symptoms, when viral replication is highest and intervention has greatest effect. Lastly, the 
reduced number of pills necessary for single versus multiple day therapy decreases the overall 
cost of treatment per episode, an important factor in modern-day healthcare.
Keywords: famciclovir, genital herpes, orolabial herpes, patient-initiated episodic therapy, 
single-day, antiviral
Introduction
Herpes simplex virus (HSV) causes an incurable viral infection that affects over 40 
million people in the United States, with over 600,000 cases diagnosed each year 
(Nadelman and Newcomer 2000). The virus spreads through close person-to-person 
contact, breeching the mucocutaneous barrier by direct mucosal penetration or through 
microabrasions in the skin. When previously unaffected individuals acquire a herpes 
infection, they develop neutralizing antibodies against HSV. Following this primary 
infection, the virus remains latent in the dorsal root ganglia until some trigger incites 
reactivation (Nadelman and Newcomer 2000). Dormancy gives these viruses the unique 
ability to cause recurrent infections in individuals who already possess neutralizing 
antibodies against them (Whitley et al 1998).
The spectrum of pathology caused by HSV include infections of the skin and 
mucous membranes (eg, orolabial herpes and genital herpes), keratoconjunctivitis, 
encephalitis, and neonatal HSV infection (Whitley et al 1998). The most common 
types of HSV infections are genital herpes and orolabial herpes (Simpson and Lyseng-
Williamson 2006). Orolabial herpes infections are usually caused by HSV type 1 Therapeutics and Clinical Risk Management 2008:4(2) 410
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(HSV-1), while 70% of ﬁ  rst episode genital herpes cases 
are caused by HSV type 2 (HSV-2) (Chosidow et al 2001). 
However, overlap exists between the two types (Nadelman 
and Newcomer 2000), and HSV-1 is becoming an increas-
ingly important causative agent of genital herpes in developed 
countries. More than 57% of the US population between the 
ages of 14 and 49 are HSV-1 seropositive (Xu et al 2006). 
Prevalence rises with increasing age in a roughly linear 
fashion, globally reaching 60–90% in older adults (Smith and 
Robinson 2002). HSV-2, however, affects a smaller propor-
tion of the population, with only 10% of 15- to 29-year-olds 
showing seropositivity. By age 60, the prevalence increases 
to approximately 35% (Whitley et al 1998).
While HSV-1 is typically acquired through non-sexual 
contact in childhood and adolescence, HSV-2 is transmit-
ted through sexual contact and is one of the most common 
sexually transmitted diseases in the world (Xu et al 2006). 
Primary HSV-2 infection often reveals itself as painful 
vesicles, pustules, and ulcerations in the anogenital area 
(Whitley et al 1998; Jungmann 2006). In males, the erup-
tion presents as vesicular lesions on an erythematous base 
on the penis, while in females, lesions occur on the cervix 
and vulva. These lesions umbilicate, erode, and form a crust 
before healing completely (Nadelman and Newcomer 2000). 
The incubation period is 2–10 days (Jungmann 2006), and 
lesions may be present for approximately 3 weeks (Whitley 
et al 1998). Viral shedding can occur throughout this entire 
period. Neutralizing antibodies develop within 2–3 weeks 
(Nadelman and Newcomer 2000).
Primary genital herpes is often more severe in women, 
who have a higher likelihood of developing complications, 
especially aseptic meningitis. In addition to burning and 
paresthesias at the affected site, both men and women may 
also experience dysuria and systemic symptoms such as 
fever, malaise, and localized inguinal adenopathy (Whitley 
et al 1998; Nadelman and Newcomer 2000).
Approximately 50% of patients with genital herpes will 
experience at least one episode of recurrence in their lifetime 
(Nadelman and Newcomer 2000). Recurrent disease tends 
to be shorter in duration, lasting 8–10 days (vs 3 weeks), 
with a shorter period of viral shedding (2–5 days). Lesions 
are less numerous and less severe; very few (approximately 
3–5) vesicles may appear on the male penis, and the female 
may only experience vulvar irritation. Generally, systemic 
symptoms do not occur during recurrent episodes. Frequency 
of recurrence correlates with the severity of primary infec-
tions; individuals who had more severe primary infections 
tend to have a greater number of recurrences. Recurrence 
is also more common in younger patients and individuals 
infected with HSV-2 compared with HSV-1 (Whitley et al 
1998; Nadelman and Newcomer 2000).
While primary genital herpes infections are rarely unrec-
ognized, primary orolabial infections are usually subclinical. 
When symptomatic, primary herpetic gingivostomatitis is the 
most common presentation, resulting in intraoral grouped 
vesicles that evolve into pustules and erosions at the site of 
inoculation, with accompanying regional lymphadenopathy, 
fever, headache, malaise, and myalgias (Wolff et al 2005). 
Like genital herpes, the virus that causes the primary infection 
travels to sensory ganglia and remains latent until opportunity 
for recurrence. Recurrent orolabial herpes, or “cold sores,” 
affect roughly one third of those who harbor the virus, variably 
presenting with prodromal burning and itching followed by a 
painful eruption of grouped vesicles on an erythematous base 
that erode and crust (Spruance et al 2006).
Although herpetic lesions in immunocompetent patients 
may heal spontaneously within 10 days, both orolabial and 
genital herpes are usually treated medically to alleviate 
patient discomfort and anxiety. Patients with severe, recur-
rent disease may suffer signiﬁ  cant quality of life impairment 
secondary to pain and disﬁ  gurement (Lorette et al 2006). 
Treatment facilitates healing, minimizing the duration of 
discomfort associated with the lesions. Meanwhile, untreated 
genital herpes has been shown to facilitate transmission of 
human immunodeﬁ  ciency virus (HIV) infection (Freeman 
et al 2006). Additionally, patients with recurrent genital her-
pes may be asymptomatic, increasing their risk of unknow-
ingly transmitting the disease to their partners from viral 
shedding. Further goals of treatment thus include reduction 
of viral shedding to limit transmission.
Currently, two treatment options are available to patients 
with recurrent genital herpes: episodic and suppressive 
therapy. Suppressive therapy involves daily oral antiviral 
agents to prevent future recurrences and is typically reserved 
for patients with frequent and/or severe outbreaks (Tyring 
et al 2006; Whitley et al 2006). Past studies have shown 
that 48% and 72% of patients on valacyclovir and famci-
clovir suppression, respectively, remain recurrence-free 
after one year, and that suppressive therapy can decrease 
the transmission of genital herpes (Diaz-Mitoma et al 1998; 
Reitano et al 1998; Corey et al 2004). Patients who are not 
sexually active or who do not wish to take daily medication 
may ﬁ  nd episodic therapy a more suitable option. With this 
alternative, antiviral treatment is initiated at the onset of a 
recurrent outbreak to limit disease progression (Tyring et al 
2006; Whitley et al 2006).Therapeutics and Clinical Risk Management 2008:4(2) 411
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In contrast to genital herpes, suppressive therapy is not 
common practice in the management of recurrent orolabial 
herpes. As only a few small-scale studies have explored this 
as a treatment option, episodic therapy continues to be the 
mainstay of treatment (Baker and Eisen 2003).
In order to limit viral replication and subsequent tissue 
damage, antiviral therapy must be initiated within the ﬁ  rst 24 
hours after prodromal or symptom onset, when viral concen-
trations are at their peak (Tyring et al 2006). Patient-initiated 
episodic therapy allows for the introduction of therapy within 
this narrow therapeutic window and confers more control 
over the disease to the patients. Additionally, patients derive 
greater beneﬁ  t from this method as patient-initiated episodic 
therapy has been shown to reduce healing time to a greater 
extent than physician-initiated therapy (Reichman et al 1984; 
Chosidow et al 2001).
Recent clinical trials have suggested that a single-day 
high-dose antiviral regimen given within the ﬁ  rst 24 hours 
of symptom onset may effectively speed healing of herpetic 
lesions. This practice harbors tremendous potential in improv-
ing patient convenience and decreasing the cost of a course 
of antiviral therapy.
Antiviral pharmacology
Currently, the only oral antiviral agents approved for treat-
ment of herpes simplex virus infections are the nucleoside 
analogues acyclovir (Zovirax®), valacyclovir (Valtrex®), and 
famciclovir (Famvir®) (Whitley et al 1998; Nadelman and 
Newcomer 2000; Jungmann 2006). Acyclovir was the ﬁ  rst 
antiviral agent to be used in the treatment of herpes infec-
tions, traditionally as a 5-day course (Reichman et al 1984). 
However, the poor bioavailability of acyclovir (approximately 
20%) necessitated 3–5 times daily dosing and prompted the 
search for more suitable agents (Crumpacker 1996; Jensen 
et al 2004). Valacyclovir, the oral prodrug of acyclovir, has 
an improved bioavailability of approximately 55% and is also 
an effective treatment option (Reitano et al 1998; Tyring et al 
1998; Leone et al 2002). Famciclovir, the oral prodrug of 
penciclovir, was found to have an even more favorable bio-
availability (77%) (Pue and Benet 1993; Tyring et al 1998), in 
addition to a longer intracellular half-life and greater afﬁ  nity 
for viral thymidine kinase than acyclovir (Vere Hodge and 
Perkins 1989; Earnshaw et al 1992).
Mechanism of action
Activation of acyclovir and penciclovir is dependent on viral 
thymidine kinase found in cells infected with herpesvirus. 
Penciclovir is rapidly converted to penciclovir-monophosphate 
by thymidine kinase and then further phosphorylated 
to penciclovir-triphosphate by other cellular enzymes. 
Similarly, acyclovir is converted intracellularly to acyclovir-
triphosphate, although at a much slower rate. This is due to 
the 100-fold higher afﬁ  nity that thymidine kinase has for 
penciclovir compared to acyclovir, leading to the more efﬁ  -
cient phosphorylation of penciclovir and higher intracellular 
concentrations of penciclovir-triphosphate versus acyclovir-
triphosphate (Boyd et al 1987; Vere Hodge and Perkins 1989; 
Earnshaw et al 1992; Pue et al 1994; Crumpacker 1996).
Both penciclovir-triphosphate and acyclovir-triphosphate 
are analogues of the naturally occurring nucleoside deoxy-
guanosine (dGTP) and compete with dGTP as a substrate for 
viral DNA polymerase. Insertion of these analogues inhibits 
viral DNA chain elongation, preventing replication of the viral 
genome. Although both penciclovir-triphosphate and acyclovir-
triphosphate act by interfering with DNA polymerase, there are 
some differences in their inhibitory mechanisms. Penciclovir-
triphosphate functions as a short-chain terminator, allowing a 
small degree of further DNA chain elongation at the 3’ hydroxyl 
group of its acyclic side chain. Acyclovir-triphosphate, however, 
is an obligate chain terminator, leading to cessation of DNA 
chain elongation after its incorporation. Additionally, DNA 
polymerase has a higher afﬁ  nity for acyclovir-triphosphate than 
penciclovir-triphosphate. Despite this fact, in a study simulating 
physiologic concentration of nucleosides, penciclovir-triphos-
phate was found to more efﬁ  ciently inhibit chain elongation 
by DNA polymerase than acyclovir-triphosphate (Reardon 
and Spector 1989; Vere Hodge and Cheng 1993; Crumpacker 
1996; Bacon et al 2003).
Overall, studies have indicated that penciclovir and 
acyclovir have similar efficacy versus varicella zoster 
virus (VZV), HSV-1, and HSV-2. This is possible despite 
the decreased afﬁ  nity of DNA polymerase for penciclo-
vir-triphosphate versus acyclovir-triphosphate given the 
aforementioned increased afﬁ  nity of thymidine kinase for 
penciclovir and the 100-fold increased intracellular con-
centrations of penciclovir-triphosphate (Larsson et al 1986; 
Earnshaw et al 1992; Vere Hodge and Cheng 1993; Bacon 
1996; Crumpacker 1996).
Plaque reduction assays have demonstrated similar 
activities of penciclovir and acyclovir when the com-
pounds are present continuously (Bacon 1996). However, 
upon withdrawal of the compounds, inhibition of virus 
replication was sustained for a greater time period with 
penciclovir than acyclovir. This sustained antiviral activity 
of penciclovir-triphosphate is due to increased stability of 
penciclovir-triphosphate, leading to prolonged intracellular Therapeutics and Clinical Risk Management 2008:4(2) 412
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concentrations and half-lives of penciclovir-triphosphate 
compared to acyclovir-triphosphate. In HSV-1 and HSV-2 
infected cells, the half-life of famciclovir is 10 and 20 hours, 
respectively. For acyclovir, the half-lives are 0.7 and 1 hour 
(Boyd et al 1987; Bacon 1996; Crumpacker 1996).
Selectivity
After absorption, penciclovir and acyclovir are taken up into 
both infected and uninfected cells. However, phosphorylation 
is dependent on viral thymidine kinase and occurs selectively 
in infected cells, sparing host DNA synthesis (Boyd et al 
1987; Vere Hodge and Perkins 1989). Cellular DNA poly-
merases have a lower afﬁ  nity for the analogue triphosphates 
when compared with viral DNA polymerases. Therefore, 
at antiviral doses, minimal concentrations of penciclovir 
(approximately 0.04 µmol/L) are isolated from uninfected 
cells and there is little inhibition of cellular DNA polymerases 
with no effect on human DNA concentrations (Earnshaw et al 
1992; Vere Hodge and Cheng 1993; Ilsley et al 1995; Bacon 
1996; Crumpacker 1996; Bacon et al 2003).
Discussion
Treatment options for genital herpes
Acyclovir was the ﬁ  rst antiviral agent to be used in the treat-
ment of genital herpes, and as such, is the most extensively 
studied of the antiviral agents currently available. This drug 
is available in topical, oral, and intravenous (IV) forms 
(Nadelman and Newcomer 2000). In the distant past, topi-
cal acyclovir was used to treat recurrent genital herpes, but 
its ineffectiveness has been known for quite some time. A 
randomized, placebo-controlled, double-blind study found 
that after application of topical acyclovir 6 times daily for 5 
days, only the duration of virus shedding from lesions was 
reduced compared to placebo. Differences between time to 
lesion crusting, lesion healing, new lesion formation, and ces-
sation of pain were non-signiﬁ  cant (Reichman et al 1983).
Intravenous acyclovir remains the most effective form 
of treatment for a primary genital herpes infection, leading 
to signiﬁ  cant reduction in time to cessation of viral shed-
ding and pain. Time to lesion healing is also 6 days faster 
than with placebo alone (8 days vs 14 days). However, as 
IV administration of acyclovir requires hospitalization, this 
route is reserved for patients with life-threatening disease or 
systemic complications (Whitley et al 1998).
Oral agents
The current standard of therapy is oral medication. In addition 
to acyclovir, valacyclovir and famciclovir are the other oral 
agents approved for treatment of recurrent genital herpes. All 
three drugs have similar efﬁ  cacy in the treatment of genital 
herpes and have been shown to expedite lesion healing time 
by approximately 1–2 days when compared with placebo 
(Sacks et al 1996; Tyring et al 1998; Chosidow et al 2001). 
Their differences are revealed in their pharmacokinetic 
properties, which dictate their dosing schedules. Acyclovir 
was traditionally dosed as 200 mg ﬁ  ve times daily for 5 
days, mainly due to its aforementioned unfavorable pharma-
cokinetic proﬁ  le (Reichman et al 1984). Such a regimen is 
extremely inconvenient and may contribute to poor patient 
compliance. Recently, however, shorter 2- to 3-day high-dose 
regimens of acyclovir and valacyclovir have also proven 
effective (Reitano et al 1998; Tyring et al 1998; Leone et al 
2002; Wald et al 2002).
Single-day treatment
Based on the recent successes of high-dose acyclovir and 
valacyclovir regimens and the unique pharmacokinetic proﬁ  le 
of famciclovir, an international, multicenter, randomized, 
double-blind, placebo-controlled trial was conducted to evalu-
ate the efﬁ  cacy of single-day famciclovir as a patient-initiated 
treatment for recurrent genital herpes in immunocompetent 
patients (Aoki et al 2006). Selection criteria stipulated that 
participants be healthy individuals with proven HSV-2 infec-
tion and at least 4 recurrences in the preceding 12 months. 
If on suppressive antiviral therapy at the time of enrollment, 
subjects must have had at least 4 recurrences in the 12 months 
prior to initiation of suppressive therapy and must have agreed 
to discontinue this therapy. 329 patients were randomized and 
given single-day famciclovir 1000 mg twice daily (n = 163) 
or matching placebo (n = 166) to take within 6 hours of the 
onset of prodromal symptoms or genital herpes lesions at 
their next recurrence. Overall, the patient demographics and 
baseline disease characteristics were well matched between 
the treatment and placebo arms.
Patients were followed daily in the clinic for the ﬁ  rst 5 
days and then every other day until all lesions had healed or 
day 14 was reached. The primary efﬁ  cacy endpoint exam-
ined was the time to healing of all non-aborted lesions, with 
secondary endpoints of efﬁ  cacy of famciclovir in inducing 
aborted lesions (deﬁ  ned as lesions that did not progress 
beyond the papule stage), time to resolution of pain and 
all other lesion-associated symptoms (deﬁ  ned as burning, 
tingling, itching, tenderness, and pain), and the safety/toler-
ability of high-dose famciclovir.
The results of this study indicated that patients treated 
with single-day, high-dose famciclovir experienced almost 
a 2-day improvement in lesion healing time (1.8 days, Therapeutics and Clinical Risk Management 2008:4(2) 413
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p  0.001; Table 1) and a signiﬁ  cant reduction in time to 
resolution of all symptoms (2.1 days, p  0.001) when com-
pared to patients treated with placebo. Furthermore, treatment 
with famciclovir halted progression to a full genital herpes 
outbreak in nearly one in four patients; aborted lesions were 
observed in 23.3% of patients in the treatment arm compared 
to only 12.7% in the placebo arm (p = 0.003). Finally, high-
dose famciclovir was well-tolerated by study participants, 
with only mild to moderate adverse events, which seemed to 
be transient in nature and similarly occurred in the placebo 
group. The most common side effects reported were head-
aches and GI distress (diarrhea, nausea, and abdominal pain), 
with headaches occurring more frequently in the treatment 
group (13.5% vs 5.4%) (Aoki et al 2006).
Comparison of therapies
Although no head-to-head trials have compared single-day 
famciclovir to the currently prescribed 2- to 5-day antiviral 
regimens, it appears to produce similar or better reduc-
tions in time to lesion healing and resolution of symptoms 
(Table 1). Additionally, single-day famciclovir also prevents 
progression to a full genital herpes outbreak as effectively 
as, or even more effectively than, other antiviral regimens. 
This single-day treatment design introduces a high load of 
antiviral agent into the body during the time of maximal viral 
replication, preventing the tissue damage and breakdown, and 
reducing symptoms that typically occur in recurrent episodes 
of genital herpes. Furthermore, single-day therapy maximizes 
patient convenience and minimizes cost (Table 2). To date, 
famciclovir is the only antiviral agent proven effective as 
single-day therapy of genital herpes.
Treatment options for orolabial herpes
Topical agents
The ﬁ  rst antiviral agents used for the treatment of recurrent 
orolabial herpes were formulated in creams. Clinical trials 
have shown that topical antivirals speed healing and lessen 
pain, but require diligent application to affected areas. The 
ﬁ  rst FDA-approved non-prescription topical medication for 
orolabial herpes was docosanol 10% cream (Abreva®), which 
demonstrated an 18-hour shorter median time to healing in 
treated patients compared to placebo (Sacks et al 2001). 
Penciclovir 1% cream (Denavir®) and acyclovir 5% cream 
(Zovirax®) are the two available prescription topical agents. 
Penciclovir 1% cream has been shown in 3 randomized, 
double-blind, placebo-controlled trials to shorten median 
healing time of cold sores by 0.7–1 day and pain duration 
by 0.6–0.8 days compared to vehicle controls (Spruance 
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et al 1997; Raborn et al 2002). Subjects in the penciclovir 
studies applied medication to the affected area within 1 hour 
of prodrome onset and continued to do so every 2 hours for 4 
consecutive days. Acyclovir 5% cream shortens the duration 
of episode by 0.5–0.6 days and duration of pain by 0.3–0.4 
days when applied 5 times a day for 4 consecutive days 
(Spruance et al 2002). Interestingly, both topical acyclovir 
and penciclovir display therapeutic efﬁ  cacy in early as well 
as late stage lesions (Spruance et al 2002).
Oral agents
Compared to topical treatments, oral agents offer the beneﬁ  t 
of less frequent dosing and increased bioavailability. Acy-
clovir, famciclovir, and valacyclovir are the most commonly 
used oral antivirals in the treatment of orolabial herpes. Oral 
acyclovir has been shown in two clinical trials to have modest 
efﬁ  cacy in decreasing healing time and duration of pain when 
given early in the prodromal stages of recurrent orolabial 
herpes. It has no effect on the development of secondary 
lesions. The current recommended dosing schedule is 400 
mg 5 times a day for 5 days (Jensen et al 2004).
Single-day treatments
Famciclovir
Oral famciclovir given as a single 1500 mg dose was FDA 
approved for the treatment of recurrent orolabial herpes 
in immunocompetent patients after the seminal work by 
Spruance and coworkers in 2006 (Spruance et al 2006). 
This randomized, double-blind, placebo-controlled study 
had patients self-initiating either a single dose of 1500 mg 
famciclovir (n = 227), 750 mg famciclovir twice a day for a 
single day (n = 220), or placebo (n = 254), within 1 hour of 
prodromal symptoms. Subjects returned to the clinic within 
24 hours for assessment. The primary efﬁ  cacy endpoint was 
healing, deﬁ  ned by loss of crust and re-epithelialization, of 
the primary vesicular lesion. The secondary efﬁ  cacy vari-
ables were time to healing of all vesicular lesions (primary 
and secondary), time to return to normal skin for all lesions 
(vesicular and aborted), and duration of pain.
Both famciclovir arms signiﬁ  cantly decreased median 
time to healing of primary vesicular lesions vs. placebo by 
1.8–2.2 days. All lesions healed a median of 2.1–2.5 days 
sooner compared to placebo. Healing time was not signiﬁ  -
cantly different between the two treatment arms. Secondary 
lesions occurred less frequently in the famciclovir-treated 
patients (11% in treated vs 18% in placebo). Compared to 
placebo, the single-dose regimen signiﬁ  cantly (p  0.001) 
lessened the duration of pain (1.7 vs 2.9 days) and time to 
return to normal skin (4.5 vs 7.0 days).
Incidence of headache and nausea in the treatment groups 
was similar to that of placebo. Headache was experienced by 
9.7%, 7.3%, and 6.7% of the single-dose (1500 mg), single-day 
(750 mg twice a day), and placebo groups, respectively. Nausea 
occurred in 2.2%, 2.3%, and 3.9% (Spruance et al 2006).
Spruance’s study demonstrated that a single 1500 mg dose 
of famciclovir by mouth reduces healing time of cold sores 
by approximately 2 days and duration of pain by approxi-
mately 1 day compared to placebo (Table 3), offering a safe 
and effective alternative for patients on episodic therapy for 
recurrent orolabial herpes.
Valacyclovir
Rapidly absorbed and hydrolyzed into acyclovir and L-valine, 
valacyclovir has three to ﬁ  ve times the bioavailability of 
Table 2 Comparison of retail cost1 of standard dosing of antiviral agents
Retail cost of oral antivirals for orolabial herpes treatment 
Drug Dose  Price  ($)
Famciclovir  1500 mg single dose (three 500 mg tablets)  28.09
Valacyclovir  2 g bid × 1 day (four 1 g tablets)  42.12
Acyclovir  400 mg tablets 5 times/day × 5 days  12.08
Retail cost of topical agents for orolabial herpes treatment 
Drug Dose  Price  ($)
Penciclovir 1% cream  Every 2 hours, 1.5 g tube  36.59
Acyclovir 5% cream  Five times/day, 2.0 g tube  48.91
Docosanol 10% cream  Five times/day, 2.0 g tube  14.99
Retail cost of oral antivirals for genital herpes treatment 
Drug Dose  Price  ($)
Famciclovir  125 mg tablets bid x 5 days  47.47
   1000 mg bid x 1 day (four 500 mg tablets)  37.46
Valacyclovir  500 mg tablets bid × 3 days  33.60
Acyclovir  800 mg tablets tid × 2 days  7.99
1Prices in US$ cited from www.drugstore.com: Drug prices and information [accessed 22 July 2007].Therapeutics and Clinical Risk Management 2008:4(2) 415
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traditional oral acyclovir (Ormrod and Goa 2000; Spruance 
et al 2003). Two large double-blind, randomized, placebo-
controlled studies demonstrated that 2 g of valacyclovir twice 
a day for 1 day (single-day treatment) and 2 g of valacyclovir 
given twice a day for 1 day followed by 1 g twice a day for 1 
day (2-day treatment) both signiﬁ  cantly shortened the time 
to healing of cold sore lesions and duration of pain compared 
to placebo. Patients initiated treatment at the ﬁ  rst sign of 
prodromal symptoms and appeared in clinic within 24 hours 
for evaluation. The primary efﬁ  cacy measure in Study 1 was 
the duration of the episode, measured from the start of treat-
ment until healing, as deﬁ  ned by loss of crust on vesicular 
lesions and return to normal skin on non-vesicular lesions. 
The primary efﬁ  cacy measure in Study 2 was the proportion 
of subjects in which cold sore development was prevented.
In the ﬁ  rst study, the single-day (n = 311) and two-day 
(n = 299) treatment groups experienced shortened duration of 
episode by a mean of 1.1 (p  0.001) and 0.7 days (p = 0.008), 
respectively, compared to placebo (n = 292). The second 
study had similar results, with both treatment arms (single-
day n = 298, 2-day n = 339) experiencing a shortened mean 
disease duration of 1.0 and 0.8 days compared to placebo 
(n = 317). There was no added beneﬁ  t in treating for 2 days 
vs 1 day. Development of new lesions was decreased in the 
treated groups, but not to a statistically signiﬁ  cant amount 
compared to placebo. The only adverse event that occurred 
with a greater frequency in the treated subjects was head-
ache: placebo (4%–5%), single-day (9%–10%), 2-day (9%) 
(Spruance et al 2003).
These two studies show that single-day high dose (2 g bid) 
course of valacyclovir safely and effectively reduces healing 
time of cold sores by an average of 1 day compared to placebo. 
There is no additional beneﬁ  t in treating for 2 days.
Comparison of therapies
While clinical trials show that topical agents are efﬁ  cacious, 
patients in the real world are unlikely to comply with the 
frequent dosing schedule required for optimal results, making 
oral antiviral agents the most convenient option for patient-
initiated episodic therapy. Although no head-to-head com-
parisons of orolabial herpes therapies exist, oral famciclovir 
and valacyclovir appear to offer similar reductions in duration 
of lesions and associated pain (Table 3). Given the similar 
efﬁ  cacy of these agents, perhaps prescribing practices should 
also be guided by a patient’s overall ﬁ  nancial circumstance, 
and accordingly we have included a cost-list of commonly 
used agents (Table 2).
Conclusion
Mucocutaneous infections caused by herpes simplex viruses 
in immunocompetent patients are usually self-limiting, 
although their impact on patient quality of life can range 
from minor annoyance to severe disability. There are sev-
eral well-recognized treatment strategies in existence, but 
single-day oral antiviral therapy for episodic treatment of 
recurrences is a new practice that has only recently been 
validated by several well-designed, large-scale clinical trials. 
While there are no studies that directly compare the efﬁ  cacy 
of different oral antivirals, available safety and efﬁ  cacy data 
support famciclovir 1500 mg once a day or valacyclovir 
2 g bid for 1 day in recurrent orolabial herpes as suitable 
ﬁ  rst-line therapies for maximizing patient convenience and 
Table 3 Efﬁ  cacy of single-day famciclovir compared to single-day valacyclovir in the treatment of recurrent orolabial herpes
Antiviral agent  Study design  Dosing  Time to loss of crust  Time to loss of crust  Duration of pain
    regimen  (median days)  (mean days)  (median days)
Famciclovir1  R, DB, PC  Patient-initiated    
 n  = 701  1500 mg single dose  4.4***  NA  1.7 (p  0.001)
    750 mg bid for 1 day  4.0***  NA  2.1 (p = 0.054)
   placebo  6.0  NA  2.9
Valacyclovir2  R, DB, PC  Patient-initiated    
Study 1  n = 902  2 g bid for 1 day  4.0***  5.0 (p  0.001)  1.2 (p = 0.009)
    2 g bid for day 1  4.5 (p = 0.009)  5.3 (p = 0.008)  1.3 (p = 0.008)
    1 g bid for day 2 (2-day)
   placebo  5.0  6.1  1.8
Study 2  n = 954  2 g bid for one day  5.0***  5.3  1.5 (p  0.001)
    2 g bid for day 1  5.0***  5.5  1.5 (p = 0.003)
    1 g bid for day 2 (2-day)
   placebo  5.5  6.3  2.2
1Spruance et al 2006, 2Spruance et al 2003.
*p  0.05, **p  0.01, ***p  0.001 vs placebo.
Abbreviations: DB, double-blind; PC, placebo-controlled; R, randomized.Therapeutics and Clinical Risk Management 2008:4(2) 416
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minimizing cost. Likewise in recurrent genital herpes, fam-
ciclovir 1000 mg bid for 1 day appears to produce similar or 
better reductions in time to lesion healing and resolution of 
symptoms than the currently prescribed 2- to 5-day antiviral 
regimens. Additionally, single-day famciclovir is effective at 
preventing progression to a full genital herpes outbreak and 
is well-tolerated. These characteristics indicate single-day 
famciclovir to be appropriate as a ﬁ  rst-line therapy.
Single-day treatment for recurrent orolabial and genital 
herpes introduces a high load of antiviral agent into the body 
during the time of maximal viral replication, limiting progres-
sion of disease. With single-day therapy, patients experience 
faster healing time, shorter duration of symptoms, while 
simultaneously regaining control over their disease through 
patient-initiated therapy.
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